| Literature DB >> 28607552 |
Juliette C Slieker1, Steve Aellen2, Philippe Eggimann3, Valentine Guarnero1, Markus Schäfer1, Nicolas Demartines1.
Abstract
BACKGROUND: Serum procalcitonin (PCT) is a useful biomarker to tailor the duration of antibiotics in respiratory infections. The objective of this study was to determine whether PCT levels could tailor postoperative antibiotic therapy in patients operated for peritonitis.Entities:
Year: 2017 PMID: 28607552 PMCID: PMC5451779 DOI: 10.1155/2017/3457614
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Institutional guidelines for duration of antibiotic therapy, based on the Surgical Infection Society guidelines [15–17].
| Indication | Duration | First choice antibiotics |
|---|---|---|
| Perforated appendicitis with peritonitis | 5 days | Amoxicillin/clavulanic acid |
| Peritonitis due to gastrointestinal perforation | 10 days | Amoxicillin/clavulanic acid. If severe infection: imipenem or piperacillin/tazobactam |
| Peritonitis due to gastrointestinal perforation, acquired in-hospital | 10 days | Imipenem or piperacillin/tazobactam |
Figure 1CONSORT diagram of included patients.
Baseline characteristics.
| Procalcitonin group | Control group |
| |
|---|---|---|---|
|
| 56 (36–73) | 57 (36–71) | 0.776 |
|
| 46 (58.2%) | 47 (57%) | 0.875 |
|
| 46 (58.2%) | 60 (72.3%) | 0.07 |
|
| 33 (41.8%) | 23 (27.7%) | |
|
| |||
| (i) Diabetes mellitus | 4 (5.1%) | 4 (4.8%) | 1.00 |
| (ii) Pulmonary | 13 (16.5%) | 7 (8.4%) | 0.15 |
| (iii) Cardiac | 29 (36.7%) | 34 (41%) | 0.63 |
| (iv) Renal dysfunction | 9 (11.4%) | 8 (9.6%) | 0.80 |
|
| 10 (12.7%) | 10 (12.0%) | 1.00 |
|
| |||
| (i) All | 19 (11–25) | 17 (12–26) | 1.00 |
| (ii) Subgroup 1 | 20 (16–26) | 21 (15.5–27.5) | |
| (iii) Subgroup 2 | 15 (10.8–21.3) | 15 (10–21) | |
| (iv) Subgroup 3 | 24.5 (17.8–29) | 28 (21–38) | |
|
| 0.91 | ||
| (i) Trouble exsudat | 5 (6.3%) | 7 (8.4%) | |
| (ii) Gastric/duodenal content | 4 (5.1%) | 5 (6.0%) | |
| (iii) Fibrinous | 3 (3.8%) | 3 (3.6%) | |
| (iv) Purulent | 53 (67.1%) | 52 (62.7%) | |
| (v) Fecal | 14 (17.7%) | 16 (19.3%) | |
|
| 0.73 | ||
| 1 | 33 (41.8%) | 28 (33.7%) | |
| 2 | 10 (12.7%) | 14 (16.7%) | |
| 3 | 3 (3.8%) | 2 (2.4%) | |
| 4 | 33 (41.8%) | 39 (47.0%) | |
|
| 31 | 33 | 0.95 |
| (i) Diverticulitis | 14 | 9 | |
| (ii) Perforated ulcer | 4 | 11 | |
| (iii) Perforation stent/colonoscopy/biopsy | 6 | 5 | |
| (iv) Ischemia–necrosis | 6 | 2 | |
| (v) High-velocity trauma | 0 | 2 | |
| (vi) Perforated tumor | 1 | 1 | |
| (vii) Other | 0 | 3 | |
|
| 34 | 39 | 0.61 |
|
| 14 | 11 | 0.43 |
| (i) Anastomotic leakage | 6 | 5 |
ASA: American Society of Anesthesiologists physical status classification system; ICU: intensive care unit.
Primary outcome measure: duration of antibiotics (median with interquartile range, days).
| Duration antibiotic treatment | Procalcitonin | Control |
|
|---|---|---|---|
| (i) All patients | 8 (5–16) | 10 (6–12) | 0.714 |
| (ii) Subgroup 1: GI perforation | 7 (5–12) | 10 (8.5–12) | 0.065 |
| (iii) Subgroup 2: appendicitis | 8 (5.5–13.5) | 8 (5–11) | 0.573 |
| (iv) Subgroup 3: postoperative | 18.5 (6.75–29.5) | 13 (11–18) | 0.403 |
Secondary outcome measures.
| Procalcitonin | Control |
| ||||
|---|---|---|---|---|---|---|
| All | Subgroup 1 ( | All | Subgroup 1 ( | All | Subgroup 1 | |
| Duration of hospitalization, d | 10 (5–24) | 10 (6–24) | 8 (4–16) | 10 (6–20) | 0.188 | 0.809 |
| Reintroduction of antibiotics | 6 (7.7%) | 3 (10%) | 5 (6.1%) | 1 (3%) | 0.762 | 0.340 |
| Reoperation | 24 (30.4%) | 6 (19.4%) | 20 (24.1%) | 7 (21.1%) | 0.383 | 1.00 |
| Relavage abdominal cavity | 10 (12.7%) | 2 (6.5%) | 7 (8.4%) | 3 (9.1%) | 0.447 | 1.00 |
| Rehospitalization | 5 (6.6%) | 1 (3.6%) | 5 (6.1%) | 2 (6.1%) | 1.00 | 1.00 |
| Positive blood cultures | 2 (2.5%) | 0 | 3 (3.6%) | 2 (6.1%) | 1.00 | 0.493 |
| Intra-abdominal abscess | 14 (17.7%) | 3 (9.7%) | 14 (16.9%) | 3 (9.1%) | 1.00 | 1.00 |
| Wound infection | 17 (21.5%) | 7 (22.6%) | 15 (18.1%) | 11 (33.3%) | 0.694 | 0.410 |
| Septic shock | 4 (5.1%) | 1 (3.2%) | 4 (4.8%) | 3 (9.1%) | 1.00 | 0.614 |
| Anastomotic leakage | 3 (3.8%) | 1 (3.2%) | 3 (3.6%) | 2 (6.1%) | 1.00 | 1.00 |
| Urinary infection | 3 (3.8%) | 2 (6.5%) | 1 (1.2%) | 0 | 0.358 | 0.231 |
| Pneumonia | 2 (2.5%) | 0 | 4 (4.8%) | 3 (9.1%) | 0.682 | 0.239 |
| Mortality | 3 (3.8%) | 3 (9.7%) | 4 (4.9%) | 3 (9.4%) | 1.00 | 1.00 |
Duration of antibiotics and duration of hospitalization are medians with interquartile range (days). All other parameters are numbers with percentages.
Figure 2Relation initial PCT value and the occurring of postoperative infectious complications. x-axis show the group of patients with (yes) and without (no) an infectious postoperative complication. y-axis shows the median PCT value on day of surgery or postoperative day 1 in μg/l (error bars 95% CI).
Figure 3Relation initial PCT value and postoperative antibiotic therapy. Scatter plot of duration of antibiotic therapy in days on x-axis versus the median PCT value on day of surgery or postoperative day 1 in μg/l. The Spearman's rank correlation coefficient r = 0.4, with a p value > 0.01.